Katherine Walsh

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

Jean‐Pierre J. Issa, Gail J. Roboz, David A. Rizzieri et al. · The Lancet Oncology · 2015 · 281 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial

Hagop M. Kantarjian, Gail J. Roboz, Patricia Kropf et al. · The Lancet Oncology · 2017 · 154 citations · Full text

Medicine, Hematology, Pharmacology +6

Anatomical risk factors that distinguish dyslexia from SLI predict reading skill in normal children

Christiana M. Leonard, Linda J. Lombardino, Katherine Walsh et al. · Journal of Communication Disorders · 2002 · 122 citations

Education, Literacy Education, Neuroscience +16

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Jason Gotlib, Aaron T. Gerds, Prithviraj Bose et al. · Journal of the National Comprehensive Cancer Network · 2018 · 105 citations · Full text

Life Sciences, Immunology, Oncology +13

Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial

Guillermo Garcia‐Manero, Gail J. Roboz, Katherine Walsh et al. · The Lancet Haematology · 2019 · 93 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +5